Upregulation of sestrins protect atriums against oxidative damage and fibrosis in human and experimental atrial fibrillation

Zengxiang Dong1,*, Chaolan Lin1,*, Yujiao Liu2,*, Hongbo Jin3,*, Hong Wu2, Zhenjun Li3, Liping Sun4, Lu Zhang4, Xi Hu4, Yingying Wei4, Chengcheng Wang4 & Wei Han1

Atrial Fibrillation (AF) is common in the elderly and Sestrins (Sesns) have been suggested to prevent age-related pathologies. The aim of this study was to investigate the effects of Sesns in AF. Clinical data were collected and a small sample of atrial appendage and atrium was obtained from patients undergoing valve repairment. The expression of Sesn1, Sesn2, and Sesn3 was significantly higher in patients with permanent atrial fibrillation (PmAf) than that in sinus rhythm (SR), and further greater in the left atrium than the right in PmAf patients. Superoxide anion and malondialdehyde were enhanced and positively correlated to the protein expression of Sesn1/2/3. Reactive oxygen species (ROS) production and Ca2+ overload were significantly decreased and cell survival was enhanced by overexpression of Sesn1/2/3 in cultured HL-1 cells. Conversely, knockdown of Sesn1/2/3 resulted in significantly increased ROS and Ca2+ overload. In addition, the overexpression of Sesn1/2 significantly reduced the proliferation of fibroblasts, as well as decreased the protein expression of collagen and fibronectin1 in angiotensin II-stimulated cardiac fibroblasts. Our study demonstrated for the first time that Sesns expression is significantly up-regulated in AF, which therefore may protect hearts against oxidative damage and atrial fibrosis.

Atrial fibrillation (AF), the most common sustained arrhythmia, affects <1% of individuals 50 to 59 years of age and 11–18% of those ≥85 years of age1,2. The lifetime risk of AF is 22–26% in men and 22–23% in women by 80 years of age in the US and Europe3,4. Aging is a slow, progressive increase in oxidative stress resulting in the accumulation of oxidized and modified proteins5. AF self-perpetuates as a result of structural and electrophysiological remodeling of the atria, which is increased by oxidative stress. Oxidative stress is present in human and experimental AF models, and antioxidants attenuate atrial electrophysiological remodeling6–8. Oxidative stress stimulates Ca2+/calmodulin-dependent protein kinase II (CaMKII) to affect intracellular Ca2+ handling and contribute to AF9. Sestrins (Sesns) are cytoplasmic stress proteins that accumulate in cells exposed to stress, hypoxia, or DNA damage5,10. Sesns were previously thought to be antioxidants that inhibit the accumulation of reactive oxygen species (ROS) by maintaining peroxiredoxin activity11–13. Overexpression of Sesn1, Sesn2, and Sesn3 reduces ROS levels, whereas depletion of Sesn1 or Sesn2 by RNA interference in cultured cells or Sesn2 knockout mice increases ROS levels12–14. Sesns are also involved in alleviating oxidative stress by eliminating ROS15–17. In addition, any condition that leads to ROS accumulation may induce Sesns expression10. Therefore, the increased atrial ROS in AF may increase the expression of Sesns. The objective of this study was to investigate whether Sesns are induced in human AF and whether they can alleviate oxidative stress, enhance cell survival and reduce fibrosis in paced HL-1 cells and cardiac fibroblasts.

1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. 2Intensive Care Unit, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, China. 3Laboratory of Physiology, Harbin Medical University, Harbin, China. 4Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to W.H. (email: hanwei2@medmail.com.cn)
Table 1. Clinical characteristics of study patients. SR = Sinus rhythm; PmAF = Permanent AF; LA = left atrium; LV = left ventricle; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blockers. *P < 0.05 compared with SR group.

|                        | SR (n = 23)          | PmAF (n = 19)         |
|------------------------|----------------------|-----------------------|
| Age, y (mean ± SD)     | 54.2 ± 8.5           | 56.3 ± 7.4            |
| Sex, men/women         | 9/14                 | 10/9                  |
| Duration of AF, y (mean ± SD) | 0                   | 4.6 ± 3.4 *          |
| Rheumatic heart disease| 8 (35%)              | 11 (58%)              |
| Valvular heart disease |                      |                       |
| Mitral valves involved | 6 (26%)              | 7 (37%)               |
| Aortic valves involved | 8 (35%)              | 2 (11%)               |
| Combined valvular disease | 9 (39%)          | 10 (53%)              |
| Diabetes mellitus      | 5 (22%)              | 1 (5%)                |
| Hypertension           | 8 (35%)              | 3 (16%)               |
| CHD                    | 7 (30%)              | 2 (11%)               |
| LA dimension, mm (mean ± SD) | 37.6 ± 4.1       | 52.9 ± 9.8 *          |
| LV end-diastolic diameter, mm (mean ± SD) | 45.7 ± 5.1      | 49.9 ± 5.6            |
| LV ejection fraction, % (mean ± SD) | 58.9 ± 4.9       | 55.1 ± 9.5            |
| Aspirin                | 6 (26%)              | 9 (47%)               |
| Warfarin               | 0                    | 5 (26%) *             |
| β-blockers             | 8 (35%)              | 10 (52%)              |
| Digoxin                | 0                    | 6 (32%) *             |
| Amiodarone             | 0                    | 1 (5%)                |
| ACE inhibitors         | 3 (13%)              | 6 (32%)               |
| Nitrates               | 2 (9%)               | 4 (21%)               |
| Statins                | 2 (9%)               | 3 (16%)               |

Results

Clinical Characteristics of Study Patients. The clinical characteristics of patients are presented in Table 1. No significant difference was identified between the groups in terms of age, sex, ratio of rheumatic heart disease, left ventricular end-diastolic diameter, and ejection fraction. However, the left atrium dimension in PmAF group was larger than that in SR group (P < 0.05), and the use of warfarin and digoxin was more common in PmAF group than in SR group. All other medications were similar between the two groups. The mean AF duration was 4.6 ± 3.4 years in the PmAF group.

Upregulation of Sesns in PmAF Patients and Cells. The location of Sesns proteins in the atrium was detected with immunofluorescence. Red fluorescence, indicating the expression of Sesns proteins, was extensively seen in the cytoplasm and nucleus of cells in PmAF group. Sesn1, Sesn2, and Sesn3 were expressed in a larger quantity in PmAF than in SR (Fig. 1A). As shown in Fig. 1A, the expression of Sesn1, Sesn2, and Sesn3 also increased in the cytoplasm and nucleus of paced HL-1 cells and AngII-stimulated cardiac fibroblasts. Furthermore, Sesns expression by western blots confirmed that PmAF had significantly elevated expression of Sesn1 (P < 0.01), Sesn2 (P < 0.01), and Sesn3 (P < 0.01) (Fig. 1B). In the PmAF group, the expression of Sesn1 (P < 0.01), Sesn2 (P < 0.01), and Sesn3 (P < 0.05) in the LA was significantly higher than in the RA. Additionally, the basal expression level of Sesn 2 in SR patients is much lower than Sesn 1 (0.39 ± 0.13 vs. 0.60 ± 0.15, P < 0.01) and Sesn 3 (0.39 ± 0.13 vs. 0.63 ± 0.24, P < 0.01). However, Sesn2 sharply increased by more than four times in AF patients, whereas Sesn 1 and Sesn 3 did not change so much.

Morphological Changes and the Relationship between Sesns and Oxidative Stress in Atrium of Patients. Collagen detected by Masson staining showed that collagen volume fraction (CVF) was 2.24 ± 0.29% in LA and RA of SR group, and this increased to 8.67 ± 0.53% and 8.22 ± 0.84% (all P < 0.01, vs. SR group) in LA and RA of AF group (Fig. 2). The amount of $O_{2}^{−}$ production in atrium was higher in PmAF patients compared with that in SR patients (P < 0.01, Fig. 3A). Malondialdehyde accumulating from LA and RA also increased significantly in the PmAF group compared with that in SR group (P < 0.01, Fig. 3B). The amount of $O_{2}^{−}$ was positively correlated to the protein expression of Sesn1 (r = 0.55, P < 0.01), Sesn2 (r = 0.57, P < 0.01), and Sesn3 (r = 0.49, P < 0.01) (Fig. 3C). A similar relationship was observed between MDA and Sesn1 (r = 0.48, P < 0.01), Sesn2 (r = 0.52, P < 0.01), and Sesn3 (r = 0.34, P < 0.01) (Fig. 3D).

Sesns Inhibit Generation of ROS in Paced HL-1 Cells. Previous reports indicated that ROS played an important role in the development of AF. To investigate the effects of Sesns on ROS in paced HL-1 cells, we expressed Sesna cDNA or Sesna siRNA in paced HL-1 cells (Fig. 4A). The overexpression and knockdown of
Sensns were documented by western blots (Fig. 4B). The amount of ROS was analyzed by flow cytometry (Fig. 5A). Pacing increased the generation of ROS in HL-1 cells from 4.5 ± 0.8% in control group to 28.8 ± 0.5% in paced group (\( P < 0.01 \)), and Sesn1, Sesn2, and Sesn3 siRNA increased the amount of ROS to 71.1 ± 0.3%, 73.3 ± 3.3% and 65.3 ± 0.4%, respectively (Fig. 5B, \( P < 0.01 \)). Moreover, the transiently expressed Sesn1, Sesn2, and Sesn3 cDNA decreased the amount of ROS to 26.1 ± 2.7%, 23.2 ± 2.3%, 32.7 ± 3.3%, respectively in paced HL-1 cells (Fig. 5B, \( P < 0.01 \)).

**Sesns Prevent Ca\(^{2+}\) Overload in Paced HL-1 Cells.** Intracellular Ca\(^{2+}\) was also monitored fluorescently in HL-1 cells. Figure 6 shows the Ca\(^{2+}\) concentration changes in HL-1 cells. Under controlled conditions, small variations in the Ca\(^{2+}\) concentrations were seen. Pacing significantly enhanced the Ca\(^{2+}\) concentration in HL-1 cells (\( P < 0.05 \)). The transient transfection of Sesn1, Sesn2, and Sesn3 siRNA significantly increased the level of Ca\(^{2+}\) in paced HL-1 cells (\( P < 0.01 \)). The elevation in intracellular Ca\(^{2+}\) was dramatically decreased by transiently expressing Sesn1, Sesn2, and Sesn3 cDNA in paced HL-1 cells (\( P < 0.01 \)).

**Sesns Enhanced Survival of Paced HL-1 Cells.** The survival rate of HL-1 cells was monitored by flow cytometry. Under controlled conditions, very small variations in the fluorescence were seen in HL-1 cells. Pacing together with transfection of PcDNA3.1 control significantly decreased the survival rate of HL-1 cells (67.5 ± 2.1% vs. 87.8 ± 4.1%, \( P < 0.01 \)) and transiently expressed Sesn1, Sesn2, and Sesn3 cDNA significantly enhanced the survival of paced HL-1 cells (76.4 ± 0.5% \( P < 0.01 \)), respectively (Fig. 7). Unexpectedly, the knockdown of Sesns by transient transfection of Sesn1, Sesn2, and Sesn3 siRNA did not decrease the survival rate of paced HL-1 cells.

**Sesns Suppress AngII-induced Proliferation of Cardiac Fibroblasts and Collagen Synthesis.** To study the effect of Sesns on cardiac fibrosis, we used CCK-8 method to detect the proliferation of cardiac fibroblasts (CFs). As Fig. 8A shows that the overexpression of Sesn1 and Sesn2 in cardiac fibroblasts significantly reduced the proliferation of fibroblasts (\( P < 0.05 \)). Next, we analyzed mRNA expression levels for COL I/III and FN1. As shown in Fig. 8B–D, Ang II induced increases of COL I/III and FN1 mRNA expression (\( P < 0.01 \)). In contrast, increased the expression of Sesn1 and Sesn2 significantly attenuated the Ang II-induced COL I and FN1 mRNA expression (\( P < 0.05 \)). To validate the mRNA findings, we identified the effect of Sesn1 and Sesn2 on protein expression of COL I/III and FN1. As shown in Fig. 8E–H, COL I/III and FN1 were severely increased induced by AngII (\( P < 0.05 \)) and the effect were clearly inhibited by Sesn1/2-overexpression (\( P < 0.05 \)). These results demonstrated Sesn1 and Sesn2 negatively regulated AngII-mediated CFs proliferation.
Figure 2. Histopathological changes in atrium of patients. Atrial collagen determined by Masson staining. Atrial collagen in the right and left atrium of patients with PmAF were significantly higher than in patients with SR. Quantification of atrial collagen is shown. SR group n = 23, PmAF group n = 19, **P < 0.01 compared with the SR group. SR = Sinus rhythm; PmAF = Permanent AF; LA = left atrium, RA = right atrium. Magnification: ×100.

Figure 3. Relationship between oxidative stress and Sesns expression in patients. (A) The amount of O$_2^-$ in SR and PmAF. (B) The amount of malondialdehyde in SR and PmAF. The production of O$_2^-$ and MDA from LA and RA increased significantly in PmAF group compared with that in SR group. (C) The amount of O$_2^-$ positively correlated with the protein expression of Sesn1, Sesn2, and Sesn3. (D) A similar relationship was observed between MDA and Sesn1, Sesn2, and Sesn3. SR group n = 23, PmAF group n = 19, **P < 0.01 compared with the SR group. SR = Sinus rhythm; PmAF = Permanent AF; LA = left atrium, RA = right atrium.
Discussion
Main Findings of the Study. The present study demonstrated for the first time that Sesns expression in RA and LA is significantly up-regulated in PmAF patients compared with that in SR. Higher \( \text{O}_2^\cdot^- \) and MDA are associated with higher Sesns expression. Furthermore, the protective effects of Sesns were confirmed by gene overexpression and knockdown in paced HL-1 cells and cardiac fibroblasts. Sesns overexpression significantly decreased oxidative stress and enhanced cell survival in paced HL-1 cells, whereas Sesns knockdown with siRNA induced ROS accumulation. Additionally, overexpression of Sesn1 and Sesn2 inhibited proliferation and collagen synthesis in cardiac fibroblasts stimulated by Ang II. Therefore, induced as an endogenous protective factor, Sesns, may protect against oxidative damage and fibrosis in AF.

Comparison with Previous Studies. Sesns are cytoplasmic stress proteins that accumulate in cells exposed to stress, hypoxia, and DNA damage\(^5,10\). Here, we identified significantly higher levels of Sesns are expressed in patients with PmAF than SR, which may be attributed to an increased oxidative stress in PmAF patients (Fig. 3). The same increase was also seen in paced HL-1 cells (Fig. 5). Studies have demonstrated that AF itself induces substantial ROS and oxidative stress in fibrillating atrial tissue\(^18,19\), thus may induce Sesns upregulation in such condition. These results are consistent with a previous study which showed that any condition which leads to ROS accumulation may induce Sesns expression\(^10,20\). Interestingly, the expression of Sesns was higher in LA than RA in PmAF, which may partly due to AF cause greater changes in \( \text{O}_2^\cdot^- \) production in the LA or LAA than in the RA or RAA\(^18\). Also, there was a trend in the more increase of oxidative stress in LA than RA in PmAF suggested by
of MDA in our study, although no statistical difference were observed (P = 0.07). An animal study of atrial tissue in AF shows a gradient of oxidative stress with greater oxidative stress on the left^{18}, however, it is not the case in human^{21,22}. Thus, besides oxidative stress, other mechanisms such as pressure, endocrine function and Ca^{2+} homeostasis^{19,23} of LA, by which the LA is distinguished from the RA, should be considered and require further investigation.

Noticeably, our study shows that there are significant basal expression level differences in Sesns. The expression of Sesn 2 in SR patients is much lower than Sesn 1 and Sesn 3, but increase more sharply than Sesn 1 and Sesn 3 in AF. This would suggest that Sesn 2 is the main subtype induced in oxidative stress in AF. Similarly, the same trend was noticed in the paced HL-1 cells in this study. Evidences were also shown in other studies that Sesn 2 is the main stress proteins induced in oxidative damage and provide significant protection in cardiovascular diseases^{24,25}. Therefore, different potencies of Sesns are induced in AF, which may suggest Sesn 2 play more important role in the pathological process of AF, whereas Sesn 1 and Sesn 3 work both in physiological and pathological conditions.

Oxidative stress drives electrical and structural remodeling, which contributes to the development and progression of AF. Anti-inflammatory and antioxidant agents prevent atrial electrical remodeling in animal models of AF and reduce the incidence of postoperative AF in humans^{6-8}. Heat shock proteins (HSPs), cytoplasmic stress proteins, are increased in AF and protect against atrial tachycardia-induced remodeling in cellular and animal models^{26-28}. Treatment with geranylgeranylacetone (GGA), an HSP inducer, increases HSP expression, suppresses refractoriness, and prevents AF in dogs subjected to atrial tachypacing^{26}. However, data are conflicting. The previous study suggested that GGA alone, without ischaemia, does not alter electrical conduction or AF duration^{29}.

Although the expression of Hsp 27 is significantly increased in paroxysmal AF compared with SR and persistent AF, no changes are observed in the expression of most HSPs, such as Hsp40, Hsc70, Hsp70, and Hsp90^{28}. Like HSP, Sesns are also cytoplasmic stress proteins, which exhibit oxidoreductase activity and may function as antioxidants^{12}. However, Sesns are widely expressed even in the absence of exogenous stress. In drosophila, expression of dSesn is increased upon maturation^{10,20}. In humans, Sesn 1, Sesn 2, and Sesn 3 are all expressed in atria without stress (shown in Fig. 1). Besides physiological conditions, we show for the first time that all kinds of Sesns are upregulated in human AF or paced HL-1 cells. These results have been consistent with previous studies, which show Sesns are cytoplasmic stress proteins accumulating in cells exposed to oxidative stress^{5,12}. Here Sesns also display protection against oxidative damage and fibrosis in experimental AF, conforming to studies that Sesns...
Sesns as a Protective Factor. The physiological functions of Sesns remain poorly defined. To our knowledge, this is the first study to report that all Sesns upregulate in human AF and protect paced cardiac myocytes against oxidative stress. Here we show that Sesns are positively correlated with oxidative stress in humans and paced HL-1 cells, which suggested oxidative stress may be the cause of Sesns upregulation in such condition. As a results, Sesns compensatory upregulate to antagonize injury induced by oxidative stress. However, this kind of compensatory mechanism is not enough to prevent the oxidative stress in AF, considering the fact that ROS accumulates in human AF and paced atrial cells in spite of theirs upregulation. Furthermore, the overexpression of Sesns decreases the amount of ROS, enhances cell survival and inhibits fibrosis in paced HL-1 cells and cardiac fibroblasts, suggesting that exogenetic Sesns may be protective and useful in AF. Some other studies also suggest that Sesns may play an important role in the regulation of cardiac pathophysiology and provide protection. In Drosophila, heart-specific depletion of dSesn caused heart dilation, arrhythmias, and malfunction. Sesn2 proteins were found to accumulate in the heart during ischemic conditions protecting the heart against ischemia and reperfusion injury. Sesn1 inhibits angiotensin II-induced fibroblast proliferation and collagen production in cardiac cells. Thus, the increase of Sesns in AF patients supports the notion that Sesns induced by ROS are an endogenous compensatory mechanism to prevent AF developing.

The mechanisms by which various types of Sesns provide cardioprotection in AF are not fully understood. The protective function of Sesns in vitro and in vivo alleviates the oxidative damage and protects in AF. The present study, Sesns overexpression decreased ROS production by 20–30% in paced HL-1 cells. In the second pathway, Sesns inhibit fibrosis, which is an important structural contributor to formation of AF substrate. We show that Sesn1 and Sesn2 inhibit cell proliferation and fibrosis in cardiac fibroblasts stimulated by AngII, which is in accordance with the findings of another study. Target of rapamycin (TOR) and TGF-beta signals are two possible mechanisms associated in the anti-fibrosis function of Sesns. Hyperactivity of TOR is related to activation of cardiac fibroblasts in stress, and the inhibition of TOR can ameliorate the chronic pressure-induced left ventricular hypertrophy and cardiac fibrosis. As an inhibitor of TOR signaling, Sesns thereby presumably attenuate fibrosis in AF.

However, the protective function of Sesns may be independent of oxidative stress, since our data show the survival of paced HL-1 cells did not grow worse in Sesns knockdown with siRNA despite the fact that apparent...
effects of introducing Sesns on oxidative stress and survival. The previous study suggested that ROS can also be protective as signal preconditioning protection and induce stress responses that lead to survival. Other mechanisms for protection are implied in the present study and should be further investigated in the future.

**Potential Significance of Sesns Upregulation in Atrial Fibrillation.** Sesns are induced in patients with PmAF, which may serve as an endogenous protective mechanism to prevent AF. Oxidative stress has been implicated in the structural and electrophysiological remodeling of AF and antioxidants prevent atrial remodeling and AF incidence. Thus, as antioxidants, Sesns probably attenuate the AF substrate and inhibit the remodeling of atria in AF. Here we show the overexpression of Sesns decreases the amount of ROS, enhances cell survival in paced HL-1 cells, as well as inhibits proliferation and collagen production in cardiac fibroblasts induced by AngII. Sesns have been demonstrated to prevent age-related pathologies, such as cancer and type II diabetes. AF is also an age-related disease and, therefore, may be prevented by Sesns. Thus, just like the effects of B-type natriuretic peptide in heart failure, our results provide novel evidences that Sesns are induced and provide protection in AF, and may serve as a possible therapeutic target in the clinical management of AF.

**Potential Limitations.** First, we demonstrated the protection of Sesns in HL-1 myocytes and cardiac fibroblasts, but not directly in AF patients. Although HL-1 cells beat spontaneously, their electrophysiological, functional, and metabolic properties are modified during culture. Second, most of the patients included in the present study had rheumatic heart disease. Although the groups were well matched for rheumatic heart disease, rheumatic fever influences oxidative stress and therefore may affect the Sesns level. Third, we did not establish a cause and effect relationship between ROS and Sesns, as well as clarify if the actions of Sesns are direct or indirect on oxidative stress. Fourth, transfection with empty vector or control RNA causes a significant increase in oxidative stress, which would influence the results of the study. Another means to introduce nucleotides which could not affect oxidative stress should be used. Fifth, the contradiction between ROS and survival indicating extra mechanisms of cardioprotection by Sesns, which is independent of oxidative stress, are implied in the present study and should be further investigated in the future.

**Summary**
Sesns are induced as an endogenous protective factor in AF, which protects the atria against oxidative damage and fibrosis. However, the compensatory increase of Sesns in AF is not enough to prevent this kind of disease, suggesting extra exogenetic Sesns are necessary and helpful for treatment of AF. This identification provides insight into the molecular basis of AF and suggests therapeutic targets for the common rhythm disturbances.
Materials and Methods

Patients. Tissue samples from the right atrium (RA) and left atrium (LA) appendage were obtained from 42 patients undergoing cardiac surgery for valvular replacement at the First Affiliated Hospital, and the Second Affiliated Hospital, Harbin Medical University, between 2011 and 2013. All patients had valvular heart disease and that a large number of patients had rheumatic heart disease. Patients were divided into two groups: permanent AF group (PmA, n = 19) in which patients have an AF history of >6 months and electrocardiographically documented AF at the time of surgery; and sinus rhythm group (SR, n = 23) in which patients had no
documented AF and no AF history. All patients were excluded liver and renal function abnormality, neoplastic disease and inflammation before surgery. The size and function of hearts were measured by echocardiography (Philips iE33, Holland). One part of the atrium and appendage tissue was fixed in 4% formalin for histopathological examination, and the remaining tissue was frozen in liquid nitrogen and stored at −80°C for immunofluorescence and western blot and other analyses. The study was approved by the Ethics Committee of the First Clinical College of Harbin Medical University, and all patients gave informed consent. All the methods were carried out in accordance with the approved guidelines.

**HL-1 Cells Culture and Pacing.** HL-1 atrial myocytes, derived from the adult mouse atra, were donated by Professor William Claycomb (Louisiana State University, New Orleans, LA, USA). The cells were cultured in complete Claycomb medium (JRH Biosciences, UK) supplemented with 100 μmol/L norepinephrine (consisting of 10 mmol/L norepinephrine (Sigma, USA) dissolved in 0.3 mmol/L L-ascorbic acid (Sigma, USA)), 4 mmol/L L-glutamine (Gibco, The Netherlands), and 10% FBS (Gibco, The Netherlands). The myocytes were incubated in flasks coated with 0.02% gelatin (Sigma, USA) and 12.5 μg/mL fibronectin (Sigma, USA) at 37 °C in a 5% CO₂ atmosphere. The basal frequency of the HL-1 cells was about 0.5 Hz. Cell models of AF were established by field stimulation 600 times per minute for 12 h (10 Hz/5 ms, 1.0 V/cm; YC-2-S stimulator, Chengdu Instrument Factory, China). Two platinum electrodes, which were positioned parallelly were used in the field pacing of HL-1 cells (shown in Fig. 4).

**Cardiac Fibroblasts Isolation and Culture.** Cardiac fibroblasts were isolated from neonatal SD rats (from the animal laboratory center of the Second Affiliated hospital of Harbin Medical University). All animal experimental procedures were approved by the ethical committee of Harbin Medical University, China and conform to published NIH guidelines for animal research (NIH Publication No. N01-OD-4–2139, 8th edition, 2011). Hearts were cut into pieces and 0.25% trypson-EDTA Solution (Beyotime biotechnology, China) was added to cells for 20–30 times. Digestive fluids were matched up one-to-one with HG-DMEM (high glucose Dulbecco’s modified Eagle medium, Gibco, The Netherlands) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% 20–30 times. Digestive fluids were matched up one-to-one with HG-DMEM (high glucose Dulbecco’s modified Eagle medium, Gibco, The Netherlands) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% 1X Penicillin-Streptomycin Solution (Gibco, The Netherlands). Then the cells were filtered and centrifuged at 2000 rpm, 4 °C for 5 minutes. Cardiomyocytes were isolated from adherent fibroblasts after incubation for 1.5 h. 0.25% trypson-EDTA and Phenol Red (Gibco, The Netherlands) was used in fibroblasts passage. The fibroblasts could be harvested while 2 times of the passages. All cells were incubated with above culture at 37 °C, 5% CO₂, 1μ M Ang II was used to stimulate cardiac fibroblasts. The proliferation of the cells was measured by CCK-8 assay.

**Sesns Overexpression and Knockdown.** Total RNA was extracted from HL-1 cells using RNAiso Plus (Takara D9108A) and cDNA was obtained using reverse transcription. Primers were synthesized by Harbin Boshi Biotechnology limited company (shown in Supplement data 1). The PCR reaction mixture included: cDNA template 2.5 μl; Ex Taq 0.5 μl; dNTP 5 μl; 10 × PCR Buffer 5 μl; Sensns 2 μl; antisense 2 μl; and dd H₂O 33 μl. Thirty-five cycles of PCR amplification were performed as follows: 94 °C for 10 minutes, 94 °C for 30 seconds, 60 °C for 30 seconds, 72 °C for 2 minutes, and 72 °C for 10 minutes. PCR products were purified with 1% agarose gel electrophoresis using AxyPrep DNA purification kit (Axygen, USA). PcDNA3.1-Sesn1, PcDNA3.1-Sesn2, and PcDNA3.1-Sesn3 were constructed by cloning cDNA into the EcoR I/Kpn I site of pcDNA3.1 vectors (Invitrogen, USA). Short interfering RNAs targeting Sesn1, Sesn2, Sesn3, and negative control were synthesized by GenePharma co, Ltd (Shanghai, China) (shown in Supplement data 2). HL-1 cells were transfected with PcDNA3.1-Sesns for 72 h or siRNA targeting Sesns for 72 h by Lipofectamine 2000 (Life Technologies, USA) in 6-well plates. Similarly, Sesn1 and Sesn2 were overexpressed in cardiac fibroblasts. Overexpression and silencing of Sesns were determined by SYBR real-time quantitative PCR with One Step SYBR PrimeScript RT-PCR Kit II (TaKaRa) ( Primer sequences were shown in Supplement data 3), as well as by western blots.

**Immunofluorescence.** Immunofluorescence staining for Sesn1, Sesn2, and Sesn3 was performed on frozen sections. Slides were permeabilized with 0.4% Triton X-100 in phosphate-buffered saline (PBS), washed, and blocked with 10% bovine serum albumin (BSA) at room temperature. The sections were incubated with anti-Sesn1 (Abcam, USA), anti-Sesn2 (Santa Cruz Biotechnology, USA), and anti-Sesn3 (Abcam, USA) antibodies, overnight at 4 °C. Slides were incubated with Alexa Fluor 594 antibodies (Molecular Probes, USA) at room temperature. Nuclei were stained with 4’, 6-diamindino-2-phenylindole (DAPI, Sigma-Aldrich, USA) and images were captured by a laser-scanning confocal microscope (Olympus, Japan). Three paraffin sections were made for every patient and three fields were evaluated in every section. Cells were seeded on glass coverslips and cultured for 24 h in DMEM (10% FBS). Cells were fixed with 4% paraformaldehyde for 20 min at room temperature. Cells were washed with PBS and blocked with 3% BSA for 1 h, then incubated with anti-Sesn1 (Abcam, USA), anti-Sesn2 (Santa Cruz Biotechnology, USA), and anti-Sesn3 (Abcam, USA) antibodies, overnight at 4 °C. They were incubated with secondary antibody (FITC, EarthOx, USA) for 2 h at 37 °C. Nuclear staining was incubated with DAPI (Sigma, St. Louis, MO, USA) at room temperature for 10 min. Cells were imaged with Carl Zeiss Axio VertA1 microscope (Carl Zeiss Microimaging, Thornwood, NY, USA).

**Real-time Quantitative Polymerase Chain Reaction (qRT-PCR) Analysis.** A quantitative analysis of collagen I (COLI), collagen III (COLIII) and fibronectin1 (FN1) mRNA expression in cardiac fibroblasts was determined by qRT-PCR. Total RNA was extracted from cardiac fibroblasts using Trizol reagent (Invitrogen, USA) according to manufacturer’s protocols. 0.5 μg of total RNA was reverse transcribed with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) to obtain cDNA. The SYBR Green PCR Master Mix Kit (Applied Biosystems, USA) was used in qRT-PCR to quantify the RNA levels of COL I, COL III and FN1 in cardiac fibroblasts, with GAPDH as an internal control. The qRT-PCR was performed on 7500 FAST Real-Time PCR System (Applied Biosystems, USA) for 40 cycles. The sequences of primers used for
amplification were: COL1, 5′-CGTGGAAAACCTGTATGCT-3′ and 5′-CCTAGACTCTTGCGTCTGG-3′; COL1I, 5′-GATCTGTACCAAGCAGATCGG AA-3′ and 5′-ATCTGTCCACCGTCTCC-3′; FN1, 5′-GACACATGCGGGTCTGACT-3′ and 5′-CCAGGCAGGATTTGTTA-3′; GAPDH, 5′-AAGATGTTGAGCGACGC-3′ and 5′-TCCACCACGGTCGTGA-3′.

Western Blot Analysis. The protein concentration in the supernatant was determined by BCA assay. Aliquots of 80 μg protein were separated in SDS-PAGE and transferred onto nitrocellulose membranes by an electric transfer (BIORAD Inc., USA). The membranes were blocked with 5% milk PBS-Tween20 (PBST) and incubated with primary antibody including: anti-Sesn1 (Abcam, USA), anti-Sesn2 (Santa Cruz Biotechnology, USA), anti-Sesn3 (Abcam, USA), anti-COL I (Abcam, USA), anti-COL III (Abcam, USA), anti-FN1 (Abcam, USA), and anti-Actin (Cell Signaling, USA) antibodies. They were then incubated with Alexa Fluor 700 antibodies (Molecular Probes, USA). Images were captured on an Odyssey Infrared Imaging System (LI-COR Biosciences, USA), and quantified using Odyssey v1.2.

Histopathological Examination. Masson’s trichrome staining for interstitial collagen deposition were analysed. Tissue specimens were fixed in 4% paraformaldehyde and embedded in paraffin. Serial sections about 5 μm in thickness were cut and stained with Masson trichrome. Sections were photographed with an Olympus HPISA-1000 camera and the extent of fibrosis was quantified with Image-Pro Plus 6.0 (Media Cybernetics, Bethesda, Md). Sections of the heart were analysed for bright blue staining (collagen) and red staining (cardiac-myocyte). Collagen volume fraction (CVF) was defined as the sum of all stained interstitial collagen tissue areas divided by the whole tissue area.

Assessment of Oxidative Stress Markers. The amount of superoxide anion (O_2•−) in the atrium was measured as described previously16. Electron spin resonance spectroscopy was used to examine intracellular O_2•− production with the cell-permeable spin probe 1-hydroxy-3-methoxy-carbonyl-2, 2, 5, 5-tetramethyl-pyrroldine hydrochloride (CMH; Alexis Corp). Briefly, freshly isolated atrial tissues was incubated with deferoxamine-chelated Krebs-HEPES solution containing CMH (0.5 mmol/L), deferoxamine (25 μmol/L), and DETC (5 μmol/L) for 90 minutes at 37 °C. Then, samples were transferred into 1-ml syringes filled with Krebs-HEPES solution and frozen in liquid nitrogen. Samples were scanned with a Bruker EMX spectrometer. Analyses of the spectra peak height were used to quantify the amount of O_2•− produced by the tissue. The amount of malondialdehyde (MDA) produced from the atrium was examined by thiobarbituric acid (TBA) assay with an MDA Detection Kit (Nanjing Jiancheng Bioengineering Institute, China). In brief, stored atrium samples were weighed and 5% tissue homogenate was obtained on ice in isotonic Na chloride. 0.1 ml tissue homogenate was processed according to the manufacturer’s instructions and detected spectrophotometrically at 532 nm by an ultraviolet spectrophotometer (GeneQuant pro, Amersham Biosciences, England).

Measurement ROS, Ca^{2+} and Apoptosis. HL-1 cells were treated with different group and incubated with 10 μM DCFH-DA (Sigma-Aldrich, USA) at 37 °C for 30 minutes for ROS detection. Fluorescence intensities of DCF were measured by excitation wave length of 488 nm and emission wave length of 525 nm with flow cytometry (BD FACS Cantor II). HL-1 cells were also loaded with the Ca^{2+} indicator Fluo 3/AM (5 μM) (Beyotime Biotechnology, China) at 37 °C for 30 minutes to measure the Ca^{2+} content within HL-1 cells. Fluor 3/AM excitation wavelength was 488 nm and emission wavelength was 525 nm. Surviving cells of different treatment group were analyzed with flow cytometry. Cell samples were prepared according to manufacturer’s instructions of Apoptosis Detection Kit I (BD Sciences, USA). The data of flow cytometry was acquired using Cell Quest software.

Statistical Analysis. Quantitative data were expressed as mean ± SEM. Differences among quantitative data were analyzed by ANOVA. Multiple comparisons were made using SNK-q test. An unpaired student’s t-test was used for comparisons between two groups. Categorical variables were analyzed by Chi-square test with continuity correction when 1 ≤ T < 5. Pearson’s correlation coefficient (r) was used to measure the strength of association between quantitative parameters. A 2-tailed P < 0.05 was considered statistically significant.

References
1. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anti-coagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370–2375 (2001).
2. Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119–125, doi: 10.1161/CIRCULATIONAHA.105.595140 (2006).
3. Lloyd-Jones, D. M. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110, 1042–1046, doi: 10.1161/01.CIR.0000140263.20897.42 (2004).
4. Magnani, J. W. et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 124, 1982–1993, doi: 10.1161/CIRCULATIONAHA.111.039677 (2011).
5. Budanov, A. V., Lee, J. H. & Karin, M. Stressin’ Sestrins take an aging fight. EMBO Mol Med 2, 388–400, doi: 10.1002/emmm.201000097 (2010).
6. Mihr, M. J. et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104, 174–180, doi: 10.1161/01.CIR.104.2.174 (2001).
7. Carnes, C. A. et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 93, E32–38 (2001).
8. Reilly, S. N. et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the arrhythmic effect of statins. Circulation 124, 1107–1117, doi: 10.1161/CIRCULATIONAHA.111.029223 (2011).
9. Purushothama, A. et al. Oxidized CaMKII triggers atrial fibrillation. Circulation 126, 1748–1757, doi: 10.1161/CIRCULATIONAHA.113.003313 (2013).
10. Lee, J. H. et al. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327, 1223–1228, doi: 10.1126/science.1182228 (2010).
fibrosis in human and experimental atrial fibrillation. Sci. Rep. 19, 2013–2023, doi: 10.1038/srep46307 (2017).

11. Budanov, A. V. & Karin, M. p53 target genes sestrin 1 and sestrin 2 connect genotoxic stress and mTOR signaling. Cell 134, 451–460, doi: 10.1016/j.cell.2008.06.028 (2008).

12. Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V. & Chumakov, P. M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304, 596–600, doi: 10.1126/science.1095569 (2004).

13. Kopnin, P. B., Agapova, L. S., Kopnin, B. P. & Chumakov, P. M. Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res 67, 4671–4678, doi: 10.1158/0008-5472.CAN-06-2466 (2007).

14. Kallenborn-Gerhardt, W. et al. Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal 19, 2013–2023, doi: 10.1089/ars.2012.4958 (2013).

15. Papadia, S. et al. Synaptic NMDA receptor activity boosts intrinsinc antioxidant defenses. Nat Neurosci 11, 476–487, doi: 10.1038/nn2071 (2008).

16. Lipton, S. A. NMDA receptor activity regulates transcription of antioxidant pathways. Nat Neurosci 11, 381–382, doi: 10.1038/nn0408-381 (2008).

17. Nogueira, V. et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14, 458–470, doi: 10.1016/j.ccr.2008.11.003 (2008).

18. Dudley, S. C. Jr. et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112, 1266–1272, doi: 10.1161/CIRCULATIONAHA.105.538108 (2005).

19. Schotten, U., Verheule, S., Kirchhof, P. & Goecke, A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91, 265–325, doi: 10.1152/physrev.00031.2009 (2011).

20. Budanov, A. V. et al. Identification of a novel stress-responsive gene H95 involved in regulation of cell viability. Oncogene 21, 6017–6031, doi: 10.1038/sj.onc.1205877 (2002).

21. Chang, J. P. et al. Atrial myocardial nox2 containing NADPH oxidase activity contribute toxicidative stress in mitral regurgitation: potential mechanism for atrial remodeling. Cardiovasc Pathol 20, 99–106, doi: 10.1016/j.carpath.2009.12.005 (2011).

22. Modrego, I. et al. Comparative expression of oxidative enzymes in blood cells from patients with mitral valve disease at sinus rhythm and atrial fibrillation. J Cardiovasc Electrophysiol 21, 859–868, doi: 10.1111/j.1540-8167.2010.01718.x (2010).

23. Cai, H. et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106, 2854–2858, doi: 10.1161/01.CIR.0000039327.16161.16 (2002).

24. Morrison, A. et al. Sestrin2 promotes LKB1-mediated AMPK activation in the ischemic heart. FASEB J 29, 408–417, doi: 10.1096/fj.14-258814 (2015).

25. Yang, Y. et al. Sestrin2 decreases renal oxidative stress, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of reactive oxygen species production. Hypertension 64, 825–832, doi: 10.1161/HYPERTENSIONAHA.114.03840 (2014).

26. Brundel, B. J. et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 99, 1394–1402, doi: 10.1161/01.RES.0000252233.83137.06 (2006).

27. Schaller, A. E. et al. The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res Cardiol 97, 258–261, doi: 10.1007/s003950020019 (2002).

28. Brundel, B. J. et al. Heat shock protein upregulation protects against pacing-induced myolysis in H1-1 atrial myocytes and human atrial fibrillation. J Mol Cell Cardiol 41, 555–562, doi: 10.1016/j.yjmcc.2006.06.068 (2006).

29. Sakabe, M. et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 78, 63–70, doi: 10.1093/cvr/cvn021 (2008).

30. Park, H. W. et al. Hepatoprotective role of Sestrin2 against chronic ER stress. Nat Commun 5, 4233, doi: 10.1038/ncomms4233 (2014).

31. Ishihara, M. et al. Sestrin-2 and BNIP3 regulate autophagy and mitophagy in renal tubular cells in acute kidney injury. Am J Physiol Renal Physiol 305, F495–509, doi: 10.1152/ajprenal.00642.2012 (2013).

32. Tao, R., Xiong, X., Liangpunsakul, S. & Dong, X. C. Sestrin 3 protein enhances hepatic insulin sensitivity by direct activation of the mTORC2-Akt signaling. Diabetes 64, 1211–1223, doi: 10.23736/S0012-4209.15-3539 (2015).

33. Liao, H. H. et al. Sestrin family may play important roles in the regulation of cardiac pathophysiologo. Int J Cardiol 202, 183–184, doi: 10.1016/j.ijcard.2015.08.164 (2015).

34. Sun, G. et al. The critical role of Sestrin 1 in regulating the proliferation of cardiac fibroblasts. Arch Biochem Biophys 542, 1–6, doi: 10.1016/j.abb.2013.11.011 (2014).

35. Dalla Costa, A. P. et al. FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex. Cardiovasc Res 86, 421–431, doi: 10.1093/cvr/cvr416 (2010).

36. Gao, X. M. et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 24, 1663–1670, doi: 10.1097/hjh.0b013e328304196.83 (2006).

37. Wempe, F. et al. Inactivation of sestrin 2 induces TGF-beta signaling and partially rescues pulmonary emphysema in a mouse model of COPD. Dis Model Mech 3, 246–253, doi: 10.1242/dmm.004224 (2010).

38. Becker, L. B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61, 461–470, doi: 10.1016/j.cardiores.2003.10.025 (2004).

39. Nascimento, E. B., Oiler, M. E. & Zierath, J. R. Sestrin 3 regulation in type 2 diabetic patients and its influence on metabolism and differentiation in skeletal muscle. Am J Physiol Endocrinol Metab 305, E1408–1414, doi: 10.1152/ajpendo.00212.2013 (2013).

40. Baxter, G. F. The natriuretic peptides. Basic Res Cardiol 99, 71–75, doi: 10.1007/s00395-004-0457-8 (2004).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017